UY26088A1 - PROTEASE INHIBITORS - Google Patents
PROTEASE INHIBITORSInfo
- Publication number
- UY26088A1 UY26088A1 UY26088A UY26088A UY26088A1 UY 26088 A1 UY26088 A1 UY 26088A1 UY 26088 A UY26088 A UY 26088A UY 26088 A UY26088 A UY 26088A UY 26088 A1 UY26088 A1 UY 26088A1
- Authority
- UY
- Uruguay
- Prior art keywords
- disease
- cartilage
- matrix
- excessive
- proteases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/12—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona inhibidores de proteasas de 4-amino-4, 5 -dihidro-benzo [b] [1, 4] dioxocin- 3 -ona, y sus sales, hidratos y solvatos farmacéuticamente aceptables que inhiben las proteasas, con inclusión de la catepsina K, composiciones farmacéuticas de tales compuestos, y métodos para tratar enfermedades de pérdida ósea excesiva o degradación excesiva de cartílago o matriz, que incluyen osteoporosis; enfermedad gingival con inclusión de gingivitis y periodontitis, artritis, más específicamente osteoartritis y artritis reumatoide; enfermedad de Paget; hipercalcemia de carácter maligno; y enfermedad metabólica ósea, que comprenden inhibir dicha pérdida ósea o degradación excesiva de cartílago o matriz por administración a un paciente que se encuentra en necesidad de ello de un compuesto de la presente invención.The present invention provides inhibitors of 4-amino-4,5-dihydro-benzo [b] [1,4] dioxocin-3 -one proteases, and their pharmaceutically acceptable salts, hydrates and solvates that inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods of treating diseases of excessive bone loss or excessive degradation of cartilage or matrix, including osteoporosis; gingival disease including gingivitis and periodontitis, arthritis, more specifically osteoarthritis and rheumatoid arthritis; Paget's disease; malignant hypercalcemia; and metabolic bone disease, which comprises inhibiting said bone loss or excessive degradation of cartilage or matrix by administration to a patient in need thereof of a compound of the present invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12725099P | 1999-03-31 | 1999-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26088A1 true UY26088A1 (en) | 2000-10-31 |
Family
ID=22429122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26088A UY26088A1 (en) | 1999-03-31 | 2000-03-29 | PROTEASE INHIBITORS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1173429A4 (en) |
JP (1) | JP2002540199A (en) |
AU (1) | AU4066900A (en) |
CO (1) | CO5180536A1 (en) |
HK (1) | HK1044758A1 (en) |
PE (1) | PE20001607A1 (en) |
UY (1) | UY26088A1 (en) |
WO (1) | WO2000058296A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034600A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
US6596715B1 (en) | 1999-11-10 | 2003-07-22 | Smithkline Beecham Corporation | Protease inhibitors |
US6534498B1 (en) | 1999-11-10 | 2003-03-18 | Smithkline Beecham Corporation | Protease inhibitors |
US7071184B2 (en) | 2000-03-21 | 2006-07-04 | Smithkline Beecham Corporation | Protease inhibitors |
US7282512B2 (en) | 2002-01-17 | 2007-10-16 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors |
JP2004196696A (en) * | 2002-12-18 | 2004-07-15 | Kyowa Hakko Kogyo Co Ltd | Arthritis-preventing or treating agent |
CN113651795B (en) * | 2021-09-14 | 2022-09-02 | 江西开源香料有限公司 | Synthesis method of watermelon ketone |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374623A (en) * | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
-
2000
- 2000-03-29 UY UY26088A patent/UY26088A1/en not_active Application Discontinuation
- 2000-03-31 EP EP00920078A patent/EP1173429A4/en not_active Withdrawn
- 2000-03-31 AU AU40669/00A patent/AU4066900A/en not_active Abandoned
- 2000-03-31 PE PE2000000283A patent/PE20001607A1/en not_active Application Discontinuation
- 2000-03-31 CO CO00023372A patent/CO5180536A1/en not_active Application Discontinuation
- 2000-03-31 JP JP2000607999A patent/JP2002540199A/en not_active Withdrawn
- 2000-03-31 WO PCT/US2000/008833 patent/WO2000058296A1/en not_active Application Discontinuation
-
2002
- 2002-06-21 HK HK02104641.3A patent/HK1044758A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HK1044758A1 (en) | 2002-11-01 |
PE20001607A1 (en) | 2001-03-07 |
EP1173429A1 (en) | 2002-01-23 |
JP2002540199A (en) | 2002-11-26 |
WO2000058296A1 (en) | 2000-10-05 |
EP1173429A4 (en) | 2002-06-19 |
CO5180536A1 (en) | 2002-07-30 |
AU4066900A (en) | 2000-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013124D0 (en) | Protease inhibitors | |
UY26625A1 (en) | PROTEASE INHIBITORS | |
AP9801222A0 (en) | Proatease inhibitors. | |
TR199902703T2 (en) | Protease inhibitors. | |
WO1999059526A3 (en) | Protease inhibitors | |
AP2002002671A0 (en) | Protease inhibitors. | |
UY26088A1 (en) | PROTEASE INHIBITORS | |
UY26026A1 (en) | PROTEASE INHIBITORS | |
UY27032A1 (en) | PROTEASE INHIBITORS | |
WO2002092563A3 (en) | Protease inhibitors | |
ECSP003403A (en) | PROTEASE INHIBITORS XI | |
ECSP993293A (en) | PROTEASE INHIBITORS VIII | |
ECSP992959A (en) | BIS-AMINOMETIL CARBONYL PROTEASE INHIBITORS | |
AR021971A1 (en) | PROTEASE INHIBITORS | |
ECSP982481A (en) | PROTEASE INHIBITORS | |
ECSP982486A (en) | PROTEASE INHIBITORS II | |
UY26771A1 (en) | PROTEASE INHIBITORS | |
ECSP003353A (en) | PROTEASE INHIBITORS IX | |
ECSP982493A (en) | PROTEASE INHIBITORS III | |
AR004703A1 (en) | HYDRAZIDIL, BIS-HYDRAZIL AND BIS-AMINOMETIL-CARBONIL, PROTEASE INHIBITORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING PROTEASES, AND USE IN THE PREPARATION OF MEDICINES. | |
UY24550A1 (en) | PROTEASE INHIBITORS | |
NZ324101A (en) | Protease inhibitors, pharmaceutical compositions and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20091022 |